Kidney Transplant Research Today is a free monthly online journal that collates and summarizes the latest research about Kidney Transplant, including details on risks, prognosis, procedure, surgery, organ donation.

Volume 2 (2005), Issue 4 (April)

1. Is noncompliance among adolescent renal transplant recipients inevitable?
   Pediatrics, 115(4): 969-73. [Abstract] [Full-text]
2. Surgical transplant physical examination: correlation of renal resistance index and biopsy-proven chronic allograft nephropathy.
   J Am Coll Surg, 200(4): 552-6. [Abstract] [Full-text]
3. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath.
   J Am Coll Surg, 200(4): 505-15; quiz A59-61. [Abstract] [Full-text]
4. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease.
   J Am Coll Cardiol, 45(7): 1051-60. [Abstract] [Full-text]
5. The effects of renal transplantation on circulating dendritic cells.
   Clin Exp Immunol, 140(2): 384-93. [Abstract] [Full-text]
6. Hepatitis B and C virus variants in long-term immunosuppressed renal transplant patients in Latvia.
   Intervirology, 48(2): 192-200. [Abstract] [Full-text]
7. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
   Nephrol Dial Transplant, 20: ii54-62. [Abstract] [Full-text]
8. Impact of HLA matching on the outcome of simultaneous pancreas-kidney transplantation.
   Nephrol Dial Transplant, 20: ii48-53, ii62. [Abstract] [Full-text]
9. A large, prospective, randomized, open-label, multicentre study of corticosteroid withdrawal in SPK transplantation: a 3-year report.
   Nephrol Dial Transplant, 20: ii40-7, ii62. [Abstract] [Full-text]
10. Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation.
    Nephrol Dial Transplant, 20: ii33-9, ii62. [Abstract] [Full-text]
11. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial.
    Nephrol Dial Transplant, 20: ii3-10, ii62. [Abstract] [Full-text]
12. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Nephrol Dial Transplant, 20: ii25-ii32, ii62. [Abstract] [Full-text]
13. Metabolic results 3 years after simultaneous pancreas-kidney transplantation.
    Nephrol Dial Transplant, 20: ii18-24, ii62. [Abstract] [Full-text]
14. Rejection after simultaneous pancreas-kidney transplantation.
    Nephrol Dial Transplant, 20: ii11-7, ii62. [Abstract] [Full-text]
15. Plasmacytoma of the urinary bladder in a renal transplant recipient.
    Int J Hematol, 81(3): 255-7. [Abstract] [Full-text]
16. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches.
    Transpl Immunol, 14(1): 53-62. [Abstract] [Full-text]
17. The cytokine gene polymorphisms in patients with chronic kidney graft rejection.
    Transpl Immunol, 14(1): 49-52. [Abstract] [Full-text]
18. Daclizumab therapy in kidney transplantation-different mechanisms of action in- versus ex-vivo?
    Transpl Immunol, 14(1): 43-7. [Abstract] [Full-text]
19. Contribution of CD4+ and CD8+ T cells and interferon-gamma to the progress of chronic rejection of kidney allografts: the Th1 response mediates both acute and chronic rejection.
    Transpl Immunol, 14(1): 21-5. [Abstract] [Full-text]
20. Preoperative administration of FTY720 prolonged renal allograft survival.
    Transpl Immunol, 14(1): 1-8. [Abstract] [Full-text]
21. Review article: current management of renal dysfunction in the cirrhotic patient.
    Aliment Pharmacol Ther, 21(8): 949-61. [Abstract] [Full-text]
22. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient.
    Am J Transplant, 5(5): 1151-8. [Abstract] [Full-text]
23. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation.
    Am J Transplant, 5(5): 1146-50. [Abstract] [Full-text]
24. Kidney allograft fibrosis and atrophy early after living donor transplantation.
    Am J Transplant, 5(5): 1130-6. [Abstract] [Full-text]
25. Consequences of eliminating HLA-B in deceased donor kidney allocation to increase minority transplantation.
    Am J Transplant, 5(5): 1090-8. [Abstract] [Full-text]
26. A comparison of long-term graft survival rates between the first and second donor kidney transplanted--the effect of a longer cold ischaemic time for the second kidney.
    Am J Transplant, 5(5): 1071-5. [Abstract] [Full-text]
27. Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy.
    Am J Transplant, 5(5): 1057-64. [Abstract] [Full-text]
28. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial.
    Am J Transplant, 5(5): 1050-6. [Abstract] [Full-text]
29. Uretero-neocystostomy in a swine model of kidney transplantation: a new technique.
    J Surg Res, 124(2): 250-5. [Abstract] [Full-text]
30. Effects of pancreas-kidney transplantation on diabetic retinopathy.
    Transpl Int, 18(5): 619-22. [Abstract] [Full-text]
31. Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature.
    Transpl Int, 18(5): 613-8. [Abstract] [Full-text]
32. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors.
    Transpl Int, 18(5): 596-603. [Abstract] [Full-text]
33. Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients.
    Transpl Int, 18(5): 590-5. [Abstract] [Full-text]
34. Sequential body composition analysis by bioimpedance early post-kidney transplantation.
    Transpl Int, 18(5): 541-7. [Abstract] [Full-text]
35. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation.
    Transpl Int, 18(5): 532-40. [Abstract] [Full-text]
36. Effect of different immunosuppressive therapies on the lipid pattern in kidney-transplanted rats.
    Transpl Int, 18(5): 524-31. [Abstract] [Full-text]
37. Postmortal or living related donor: preferences of kidney patients.
    Transpl Int, 18(5): 519-23. [Abstract] [Full-text]
38. Fibrosis and matrix metalloproteinases in rat renal allografts.
    Transpl Int, 18(5): 506-12. [Abstract] [Full-text]
39. Bilateral subchondral insufficiency fracture of the femoral head after renal transplantation: a case report.
    Arthritis Rheum, 52(4): 1293-6. [Abstract] [Full-text]
40. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.
    Nephrol Dial Transplant, 20(5): 974-80. [Abstract] [Full-text]
41. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Nephrol Dial Transplant, 20(5): 968-73. [Abstract] [Full-text]
42. Rare cause of ureteral stenosis more than 10 years after kidney transplantation.
    Urology, 65(4): 798. [Abstract] [Full-text]
43. Evaluation of bone-mineral density by digital X-ray radiogrammetry (DXR) in pediatric renal transplant recipients.
    Pediatr Radiol, 35(5): 489-94. [Abstract] [Full-text]
44. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation.
    Contemp Clin Trials, 26(1): 17-24. [Abstract] [Full-text]
45. Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation.
    Pediatr Nephrol, 20(5): 652-6. [Abstract] [Full-text]
46. Cyclosporine A monitoring--how to account for twice and three times daily dosing.
    Pediatr Nephrol, 20(5): 591-6. [Abstract] [Full-text]
47. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
    Biopharm Drug Dispos, 26(4): 135-41. [Abstract] [Full-text]
48. Sirolimus rescue of renal failure in children after combined liver-kidney transplantation.
    Pediatr Nephrol, 20(5): 686-9. [Abstract] [Full-text]
49. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system.
    J Clin Invest, 115(4): 1092-9. [Abstract] [Full-text]
50. Kidney paired donation and optimizing the use of live donor organs.
    JAMA, 293(15): 1883-90. [Abstract] [Full-text]
51. Insulin resistance, LDL particle size, and LDL susceptibility to oxidation in pediatric kidney and liver recipients.
    Kidney Int, 67(5): 2046-55. [Abstract] [Full-text]
52. A prospective randomized study for prevention of postrenal transplantation bone loss.
    Kidney Int, 67(5): 2039-45. [Abstract] [Full-text]
53. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation.
    Kidney Int, 67(5): 2015-20. [Abstract] [Full-text]
54. Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B in kidney transplant recipients.
    Kidney Int, 67(5): 1980-5. [Abstract] [Full-text]
55. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion.
    Kidney Int, 67(5): 1753-61. [Abstract] [Full-text]
56. Cellular transplantation of nephrons.
    Kidney Int, 67(5): 1677-9. [Abstract] [Full-text]
57. Altered expression of aquaporin-2 in human explants with chronic renal allograft dysfunction.
    BJU Int, 95(7): 1104-8. [Abstract] [Full-text]
58. Interventions for preventing bone disease in kidney transplant recipients.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
59. Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
60. A randomized, double-blind comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation.
    Anesth Analg, 100(5): 1518-24, table of contents. [Abstract] [Full-text]
61. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Transplant Proc, 37(2): 1301-4. [Abstract] [Full-text]
62. Incidence of coronary heart disease and cardiac events in patients undergoing kidney and pancreatic transplantation.
    Transplant Proc, 37(2): 1297-300. [Abstract] [Full-text]
63. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
    Transplant Proc, 37(2): 1294-6. [Abstract] [Full-text]
64. A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation.
    Transplant Proc, 37(2): 1289-90. [Abstract] [Full-text]
65. Comparable kidney graft survival of type 1 diabetics treated with simultaneous pancreas-kidney transplantation and nondiabetic patients treated with cadaveric renal transplantation.
    Transplant Proc, 37(2): 1285-6. [Abstract] [Full-text]
66. Simultaneous pancreas-kidney transplants in type I and type II diabetic patients with end-stage renal disease: similar 10-year outcomes.
    Transplant Proc, 37(2): 1283-4. [Abstract] [Full-text]
67. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
    Transplant Proc, 37(2): 1280-2. [Abstract] [Full-text]
68. Multivariate analysis of the influence of donor and recipient cytomegalovirus sero-pairing on outcomes in simultaneous kidney-pancreas transplantation: the South-Eastern Organ Procurement Foundation Experience.
    Transplant Proc, 37(2): 1271-3. [Abstract] [Full-text]
69. Donors with a maximum body weight of 50 kg for simultaneous pancreas-kidney transplantation.
    Transplant Proc, 37(2): 1268-70. [Abstract] [Full-text]
70. Genotypic resistance of hepatitis B virus to lamivudine in renal transplant recipients.
    Transplant Proc, 37(2): 1235-7. [Abstract] [Full-text]
71. Ureteric complications of renal transplantation: the impact of the double J stent and the anterior extravesical ureteroneocystostomy.
    Transplant Proc, 37(2): 1054-6. [Abstract] [Full-text]
72. Effect of routine insertion of a double-J stent after living related renal transplantation.
    Transplant Proc, 37(2): 1052-3. [Abstract] [Full-text]
73. Renovascular reconstruction of grafts with renal artery variations in living kidney transplantation.
    Transplant Proc, 37(2): 1049-51. [Abstract] [Full-text]
74. Efficacy and safety of Palmaz stent implantation in the treatment of renal artery stenosis in renal transplantation.
    Transplant Proc, 37(2): 1047-8. [Abstract] [Full-text]
75. A simple cardiovascular risk score can predict poor outcome in non-heart-beating donor renal transplantation.
    Transplant Proc, 37(2): 1044-6. [Abstract] [Full-text]
76. Cardiovascular effects of successful renal transplantation: a 30-month study on left ventricular morphology, systolic and diastolic functions.
    Transplant Proc, 37(2): 1039-43. [Abstract] [Full-text]
77. Cyclosporine and tacrolimus: influence on cardiovascular risk factors.
    Transplant Proc, 37(2): 1036-8. [Abstract] [Full-text]
78. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population.
    Transplant Proc, 37(2): 1033-5. [Abstract] [Full-text]
79. Weight gain after living-related renal transplantation affects long-term graft function.
    Transplant Proc, 37(2): 1029-32. [Abstract] [Full-text]
80. Increased risk of hemorrhagic complications in renal allograft recipients receiving systemic heparin early posttransplantation.
    Transplant Proc, 37(2): 1026-8. [Abstract] [Full-text]
81. Influence of vitamin D receptor gene polymorphisms on secondary hyperparathyroidism and bone density after kidney transplantation.
    Transplant Proc, 37(2): 1023-5. [Abstract] [Full-text]
82. Evaluation of cortical bone by peripheral quantitative computed tomography in renal transplant recipients.
    Transplant Proc, 37(2): 1020-2. [Abstract] [Full-text]
83. Changes in bone mineral density and selected metabolic parameters over 24 months following renal transplantation.
    Transplant Proc, 37(2): 1014-9. [Abstract] [Full-text]
84. Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis.
    Transplant Proc, 37(2): 1012-3. [Abstract] [Full-text]
85. Predictive factors of postrenal transplant anemia.
    Transplant Proc, 37(2): 1009-11. [Abstract] [Full-text]
86. Iron deficiency--an underrecognized problem in nonanemic and erythrocytic kidney transplant recipients: risks and effects of ACEI and of iron treatment.
    Transplant Proc, 37(2): 1007-8. [Abstract] [Full-text]
87. Are anemic patients more sensitive to calcineurin inhibitors?
    Transplant Proc, 37(2): 1005-6. [Abstract] [Full-text]
88. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation.
    Transplant Proc, 37(2): 1001-4. [Abstract] [Full-text]
89. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus.
    Transplant Proc, 37(2): 999-1000. [Abstract] [Full-text]
90. Blood pressure and graft outcome in renal transplantation.
    Transplant Proc, 37(2): 997-8. [Abstract] [Full-text]
91. Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients.
    Transplant Proc, 37(2): 994-6. [Abstract] [Full-text]
92. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Transplant Proc, 37(2): 991-3. [Abstract] [Full-text]
93. Tubular and glomerular proteinuria in diagnosing chronic allograft nephropathy with relevance to the degree of urinary albumin excretion.
    Transplant Proc, 37(2): 987-90. [Abstract] [Full-text]
94. Analysis of allograft biopsy specimens in renal transplants with proteinuria: is proteinuria a culprit of graft loss?
    Transplant Proc, 37(2): 984-6. [Abstract] [Full-text]
95. Loss of peritubular capillaries in the development of chronic allograft nephropathy.
    Transplant Proc, 37(2): 981-3. [Abstract] [Full-text]
96. Hypothesis: epithelial-to-mesenchymal transition is a common cause of chronic allograft failure.
    Transplant Proc, 37(2): 977-80. [Abstract] [Full-text]
97. Parathyroidectomy for parathyroid carcinoma in renal transplantation.
    Transplant Proc, 37(2): 973-6. [Abstract] [Full-text]
98. Mutation scanning of the p53 tumor suppressor gene in renal and liver transplant patients in Hungary.
    Transplant Proc, 37(2): 969-72. [Abstract] [Full-text]
99. Kaposi's sarcoma in renal transplant patients: predisposing factors and prognosis.
    Transplant Proc, 37(2): 967-8. [Abstract] [Full-text]
100. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment.
     Transplant Proc, 37(2): 964-6. [Abstract] [Full-text]
101. Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience.
     Transplant Proc, 37(2): 958-9. [Abstract] [Full-text]
102. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience.
     Transplant Proc, 37(2): 956-7. [Abstract] [Full-text]
103. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement.
     Transplant Proc, 37(2): 954-5. [Abstract] [Full-text]
104. Successful vaccination against varicella zoster virus prior to kidney transplantation.
     Transplant Proc, 37(2): 952-3. [Abstract] [Full-text]
105. Polyoma BK virus reactivation in kidney and pancreas-kidney recipients.
     Transplant Proc, 37(2): 947-8. [Abstract] [Full-text]
106. Human polyoma virus in kidney transplants: SV40 T-antigen demonstration in the urine.
     Transplant Proc, 37(2): 945-6. [Abstract] [Full-text]
107. Outcomes of patients with rejection post-polyomavirus nephropathy.
     Transplant Proc, 37(2): 942-4. [Abstract] [Full-text]
108. Natural history of hepatitis C virus infection in adult renal graft recipients.
     Transplant Proc, 37(2): 940-1. [Abstract] [Full-text]
109. Mycobacterial infections after kidney transplant.
     Transplant Proc, 37(2): 937-9. [Abstract] [Full-text]
110. Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation.
     Transplant Proc, 37(2): 930-3. [Abstract] [Full-text]
111. Deoxyspergualin prophylaxis with tacrolimus further improves long-term graft survival in living-related renal-transplant recipients transfused with donor-specific blood.
     Transplant Proc, 37(2): 927-9. [Abstract] [Full-text]
112. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
     Transplant Proc, 37(2): 923-6. [Abstract] [Full-text]
113. Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies: 12-month results of a randomized, multicentre, open, prospective controlled study.
     Transplant Proc, 37(2): 920-2. [Abstract] [Full-text]
114. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
     Transplant Proc, 37(2): 916-9. [Abstract] [Full-text]
115. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
     Transplant Proc, 37(2): 912-5. [Abstract] [Full-text]
116. Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients.
     Transplant Proc, 37(2): 909-11. [Abstract] [Full-text]
117. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation.
     Transplant Proc, 37(2): 906-8. [Abstract] [Full-text]
118. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
     Transplant Proc, 37(2): 903-5. [Abstract] [Full-text]
119. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
     Transplant Proc, 37(2): 899-902. [Abstract] [Full-text]
120. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
     Transplant Proc, 37(2): 895-8. [Abstract] [Full-text]
121. Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety.
     Transplant Proc, 37(2): 892-4. [Abstract] [Full-text]
122. Multivariate analysis of antibody induction therapy and their associated outcomes in deceased donor transplants.
     Transplant Proc, 37(2): 889-91. [Abstract] [Full-text]
123. Multivariate analysis of the effectiveness of using antibody induction therapy according to the degree of HLA mismatches.
     Transplant Proc, 37(2): 886-8. [Abstract] [Full-text]
124. The safety and efficacy of early withdrawal of calcineurin inhibitors in kidney transplant recipients 6 months' posttransplant.
     Transplant Proc, 37(2): 884-5. [Abstract] [Full-text]
125. Excellent results with calcineurin inhibitor-free initial immunosuppression in old recipients of old kidneys.
     Transplant Proc, 37(2): 881-3. [Abstract] [Full-text]
126. The effect of urinary protein excretion in post-renal transplant recurrent nephrotic syndrome on basiliximab pharmacokinetics and pharmacodynamics in a pediatric patient.
     Transplant Proc, 37(2): 879-80. [Abstract] [Full-text]
127. Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient.
     Transplant Proc, 37(2): 875-8. [Abstract] [Full-text]
128. Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection.
     Transplant Proc, 37(2): 871-4. [Abstract] [Full-text]
129. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.
     Transplant Proc, 37(2): 867-70. [Abstract] [Full-text]
130. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
     Transplant Proc, 37(2): 864-6. [Abstract] [Full-text]
131. Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients.
     Transplant Proc, 37(2): 861-3. [Abstract] [Full-text]
132. Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients.
     Transplant Proc, 37(2): 859-60. [Abstract] [Full-text]
133. Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients.
     Transplant Proc, 37(2): 856-8. [Abstract] [Full-text]
134. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
     Transplant Proc, 37(2): 852-5. [Abstract] [Full-text]
135. Does mycophenolate mofetil increase the incidence of cytomegalovirus disease compared with azathioprine after cadaveric kidney transplantation?
     Transplant Proc, 37(2): 850-1. [Abstract] [Full-text]
136. Gastrointestinal-specific patient-reported outcome instruments differentiate between renal transplant patients with or without GI complications.
     Transplant Proc, 37(2): 846-9. [Abstract] [Full-text]
137. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
     Transplant Proc, 37(2): 839-42. [Abstract] [Full-text]
138. Severe limb lymphedema in sirolimus-treated patients.
     Transplant Proc, 37(2): 834-6. [Abstract] [Full-text]
139. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
     Transplant Proc, 37(2): 827-9. [Abstract] [Full-text]
140. Rabbit antithymocyte globulin: a postoperative risk factor for sirolimus-treated renal transplant patients?
     Transplant Proc, 37(2): 822-6. [Abstract] [Full-text]
141. Effect of race on the occurrence of posttransplant diabetes in kidney transplant recipients treated with early steroid discontinuation.
     Transplant Proc, 37(2): 819-21. [Abstract] [Full-text]
142. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis.
     Transplant Proc, 37(2): 817-8. [Abstract] [Full-text]
143. African American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression.
     Transplant Proc, 37(2): 814-6. [Abstract] [Full-text]
144. Global cardiovascular risk under early corticosteroid cessation decreases progressively in the first year following renal transplantation.
     Transplant Proc, 37(2): 812-3. [Abstract] [Full-text]
145. A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report.
     Transplant Proc, 37(2): 804-8. [Abstract] [Full-text]
146. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience.
     Transplant Proc, 37(2): 802-3. [Abstract] [Full-text]
147. Early corticosteroid withdrawal under modern immunosuppression in renal transplantation: multivariate analysis of risk factors for acute rejection.
     Transplant Proc, 37(2): 798-9. [Abstract] [Full-text]
148. Comparative study of clinical outcome in kidney transplantation between early steroid withdrawal protocol using basiliximab, calcineurin inhibitor, and mycophenolate mofetil and triple regimen consisting of calcineurin inhibitor, mycophenolate mofetil, and steroid.
     Transplant Proc, 37(2): 791-4. [Abstract] [Full-text]
149. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.
     Transplant Proc, 37(2): 788-90. [Abstract] [Full-text]
150. Long-term evolution of lymphocytes subsets after induction therapy based on continuous versus discontinuous administration of anti-thymocyte globulins in renal-transplant patients.
     Transplant Proc, 37(2): 785-7. [Abstract] [Full-text]
151. Expression of CD158b on peripheral blood lymphocytic cell after kidney transplantation.
     Transplant Proc, 37(2): 782-4. [Abstract] [Full-text]
152. Reduction of immunosuppressive load in renal transplant recipients with a low donor-specific cytotoxic T-lymphocyte precursor frequency is safe.
     Transplant Proc, 37(2): 779-81. [Abstract] [Full-text]
153. Endothelial nitric oxide synthase and angiotensin II type 1 receptor gene polymorphisms can influence chronic inflammatory state in renal transplant patients.
     Transplant Proc, 37(2): 776-8. [Abstract] [Full-text]
154. Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients.
     Transplant Proc, 37(2): 773-5. [Abstract] [Full-text]
155. Mycophenolate mofetil but not the type of calcineurin inhibitor (cyclosporine vs tacrolimus) influences the intragraft mRNA expression of cytokines in human kidney allograft biopsies by in situ RT-PCR analysis.
     Transplant Proc, 37(2): 770-2. [Abstract] [Full-text]
156. Intragraft mRNA expression of cytokines and growth factors in human kidney allograft biopsies by in situ RT-PCR analysis.
     Transplant Proc, 37(2): 767-9. [Abstract] [Full-text]
157. Effect of cytokines and chemokines (TGF-beta, TNF-alpha, IL-6, IL-10, MCP-1, RANTES) gene polymorphisms in kidney recipients on posttransplantation outcome: influence of donor-recipient match.
     Transplant Proc, 37(2): 764-6. [Abstract] [Full-text]
158. Cytokines and chemokine gene expression in human kidney transplantation.
     Transplant Proc, 37(2): 760-3. [Abstract] [Full-text]
159. The influence of angiotensin-converting enzyme gene of donor and recipient on the function of transplanted kidney.
     Transplant Proc, 37(2): 755-9. [Abstract] [Full-text]
160. Granzyme B ELISPOT assay determines the cytotoxic T lymphocyte precursor frequency after HLA-identical living-related kidney transplantation.
     Transplant Proc, 37(2): 752-4. [Abstract] [Full-text]
161. Immunomonitoring of renal transplant recipients in the early posttransplant period by sequential analysis of chemokine and chemokine receptor gene expression in peripheral blood mononuclear cells.
     Transplant Proc, 37(2): 747-51. [Abstract] [Full-text]
162. Demographic analysis and outcome features in a transplant outpatient clinic.
     Transplant Proc, 37(2): 743-6. [Abstract] [Full-text]
163. Allogeneic hematopoietic stem-cell transplantation, mixed chimerism, and tolerance in living related donor renal allograft recipients.
     Transplant Proc, 37(2): 737-42. [Abstract] [Full-text]
164. Conversion of azathioprine to mycophenolate mofetil and chronic graft failure progression.
     Transplant Proc, 37(2): 734-6. [Abstract] [Full-text]
165. Accurate prediction of kidney allograft outcome based on creatinine course in the first 6 months posttransplant.
     Transplant Proc, 37(2): 731-3. [Abstract] [Full-text]
166. Significant differences in the efficacy of kidney transplantation between Hungarian Caucasians and Gypsies.
     Transplant Proc, 37(2): 729-30. [Abstract] [Full-text]
167. The impact of gender and age matching for long-term graft survival in living donor renal transplantation.
     Transplant Proc, 37(2): 726-8. [Abstract] [Full-text]
168. Renal transplantation in patients over 65 years of age: no more a contraindication but a growing indication.
     Transplant Proc, 37(2): 721-5. [Abstract] [Full-text]
169. Does pretransplant obesity affect the outcome in kidney transplant recipients?
     Transplant Proc, 37(2): 717-20. [Abstract] [Full-text]
170. Renal biopsy donor group: the influence of glomerulosclerosis on transplant outcomes.
     Transplant Proc, 37(2): 712-3. [Abstract] [Full-text]
171. Baseline glomerular sclerosis influences morphological changes, but not level of serum creatinine.
     Transplant Proc, 37(2): 709-11. [Abstract] [Full-text]
172. Protocol biopsies in kidney transplant recipients: histologic findings as prognostic markers for graft function and outcome.
     Transplant Proc, 37(2): 705-8. [Abstract] [Full-text]
173. Reversibility from delayed hyperacute rejection in ABO-incompatible renal transplantation: histopathological findings of renal allograft biopsy.
     Transplant Proc, 37(2): 701-4. [Abstract] [Full-text]
174. Transplantation of single pediatric kidneys into adult recipients.
     Transplant Proc, 37(2): 697-8. [Abstract] [Full-text]
175. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
     Transplant Proc, 37(2): 693-6. [Abstract] [Full-text]
176. Long-term graft outcome of living donor renal transplantation: single center experience.
     Transplant Proc, 37(2): 690-2. [Abstract] [Full-text]
177. Twenty-five-year survival of living related kidney transplants: thirty-five years' experience.
     Transplant Proc, 37(2): 687-9. [Abstract] [Full-text]
178. Cadaveric kidney transplantation in children < or =20 kg in weight: long-term single-center experience.
     Transplant Proc, 37(2): 685-6. [Abstract] [Full-text]
179. Sirolimus in pediatric renal transplantation.
     Transplant Proc, 37(2): 682-4. [Abstract] [Full-text]
180. Predictive value of pretransplant inflammatory markers in renal allograft survival and rejection in children.
     Transplant Proc, 37(2): 679-81. [Abstract] [Full-text]
181. Long-term results of pediatric renal transplantation at one center in Turkey.
     Transplant Proc, 37(2): 675-8. [Abstract] [Full-text]
182. Open-label, multicenter study on the safety, tolerability, and efficacy of Simulect in pediatric renal transplant recipients receiving triple therapy with cyclosporin, mycophenolate, and corticosteroids.
     Transplant Proc, 37(2): 672-4. [Abstract] [Full-text]
183. Standardized psychological evaluation pre- and posttransplantation: a new option.
     Transplant Proc, 37(2): 669-71. [Abstract] [Full-text]
184. Pretransplant nephrectomy in patients with autosomal dominant polycystic kidney disease.
     Transplant Proc, 37(2): 666-8. [Abstract] [Full-text]
185. The effect of renal transplantation on pulmonary function and respiratory muscle strength in patients with end-stage renal disease.
     Transplant Proc, 37(2): 664-5. [Abstract] [Full-text]
186. An evaluation of HLA cross-reactive group matching on graft survival in deceased donor kidney recipients.
     Transplant Proc, 37(2): 661-3. [Abstract] [Full-text]
187. Significant HLA matching effect in a large urban transplant center composed primarily of minorities.
     Transplant Proc, 37(2): 658-60. [Abstract] [Full-text]
188. Vimentin antibodies: a non-HLA antibody as a potential risk factor in renal transplantation.
     Transplant Proc, 37(2): 654-7. [Abstract] [Full-text]
189. Management of end-stage renal disease patients with antiphospholipid antibody syndrome.
     Transplant Proc, 37(2): 650-1. [Abstract] [Full-text]
190. Are autoimmune diseases or glomerulonephritis affecting the development of panel-reactive antibodies in candidates for renal transplantation?
     Transplant Proc, 37(2): 645-7. [Abstract] [Full-text]
191. Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis.
     Transplant Proc, 37(2): 643-4. [Abstract] [Full-text]
192. Routine use of renal-dose dopamine during living donor nephrectomy has no beneficial effect to either donor or recipient.
     Transplant Proc, 37(2): 637-9. [Abstract] [Full-text]
193. Laparoscopic right living donor nephrectomy.
     Transplant Proc, 37(2): 631-2. [Abstract] [Full-text]
194. Alterations in the practice of open and laparoscopic live donor nephrectomy at renal transplant centers in the UK and Ireland.
     Transplant Proc, 37(2): 623-4. [Abstract] [Full-text]
195. Warm ischemic time during laparoscopic live donor nephrectomy: effects on graft function.
     Transplant Proc, 37(2): 620-2. [Abstract] [Full-text]
196. Outcome of assessment of potential donors for live donor kidney transplants.
     Transplant Proc, 37(2): 605-6. [Abstract] [Full-text]
197. Influence of educational programs on perceived barriers toward living donor kidney exchange programs.
     Transplant Proc, 37(2): 602-4. [Abstract] [Full-text]
198. Nonresident living kidney donors.
     Transplant Proc, 37(2): 598-9. [Abstract] [Full-text]
199. The Dutch algorithm for allocation in living donor kidney exchange.
     Transplant Proc, 37(2): 589-91. [Abstract] [Full-text]
200. Central nervous system tumors in donors: misdiagnosis carries a high morbidity and mortality.
     Transplant Proc, 37(2): 583-4. [Abstract] [Full-text]
201. Donor kidneys with small renal cell cancers: can they be transplanted?
     Transplant Proc, 37(2): 581-2. [Abstract] [Full-text]
202. Kidney transplantation from donors aged 65 years or more as single or dual grafts.
     Transplant Proc, 37(2): 577-80. [Abstract] [Full-text]
203. Afghan refugees in Iran model renal transplantation program: ethical considerations.
     Transplant Proc, 37(2): 565-7. [Abstract] [Full-text]
204. Living-unrelated (paid) renal transplantation--ten years later.
     Transplant Proc, 37(2): 563-4. [Abstract] [Full-text]
205. Living paid organ transplantation results in unacceptably high recipient morbidity and mortality.
     Transplant Proc, 37(2): 560-2. [Abstract] [Full-text]
206. Assessing health status and health care utilization in adolescents with chronic kidney disease.
     J Am Soc Nephrol, 16(5): 1427-32. [Abstract] [Full-text]
207. Factors associated with improvement in deceased donor renal allograft function in the 1990s.
     J Am Soc Nephrol, 16(5): 1512-21. [Abstract] [Full-text]
208. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
     J Am Soc Nephrol, 16(5): 1501-11. [Abstract] [Full-text]
209. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation.
     J Am Soc Nephrol, 16(5): 1494-500. [Abstract] [Full-text]
210. Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients.
     Int J Cardiol, 101(1): 9-17. [Abstract] [Full-text]

© 2004-2008 Kidney Transplant Research Today. All Rights Reserved.